GlassScriptPhysician profile
Philip S Lo
NPI 1700841012
$2,553.58
in general payments reported to CMS, 2019-2025
12 companies · $715 in 2025
The $715 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $100 · 2021: $103 · 2022: $184 · 2023: $491 · 2024: $652 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $623.11 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $526.14 | 2021-2025 | Acrysof Iq Panoptix Uv Iol, Precision 1, Dailies Total1 |
| Bausch & Lomb Americas INC. | $424.22 | 2023-2025 | Infuse, Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $232.67 | 2020-2024 | Acuvue |
| Sun Pharmaceutical Industries INC. | $220.29 | 2020-2025 | Cequa |
| Optos, INC. | $186.16 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $149.99 | 2025 | |
| Oyster Point Pharma, INC. | $62.32 | 2022-2024 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.98 | 2019 | |
| Abb Con-Cise Optical Group LLC | $28.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.11 | 2022-2023 | |
| Biotissue Holdings INC. | $21.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.